RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate
Source: SeekingAlpha
2026-01-20 15:15:45 ET
The last time I spoke about RAPT Therapeutics, Inc. ( RAPT ), it was in a Seeking Alpha article entitled " RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus ." With respect to this article, I primarily noted the development of its CCR4 antagonist zelnecirnon [RPT193] for the treatment of patients with asthma and atopic dermatitis [AD]. The drug was being evaluated to treat these patients in phase 2 clinical testing. The hope was that the FDA clinical hold would end up being lifted from this program....
Read the full article on Seeking Alpha
For further details see:
RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate
GlaxoSmithKline Plc
NASDAQ: GLAXF
GLAXF Trading
0.0% G/L:
$27.11 Last:
101 Volume:
$27.11 Open:
GLAXF Latest News
GLAXF Stock Data
$123,941,620,346
2,019,018,428
0.4%
538
N/A
Pharmaceuticals
Healthcare
GB
London
